The DMD Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DMD gene in the NCI-H1299 human lung adenocarcinoma cell line. This model provides a heterogeneous pool of cells with disrupted dystrophin expression, enabling loss-of-function studies without the bottleneck effects of clonal selection. The product is formatted as polyclonal cells to capture diverse editing outcomes and average population-level phenotypes.
NCI-H1299 is a p53-deficient, KRAS wild-type cell line derived from a lymph node metastasis of lung adenocarcinoma, widely used for investigating metastatic mechanisms and cancer drug responses. Its invasive nature and genetic tractability make it an ideal host for studying genes implicated in tumor progression.
Dystrophin, encoded by DMD, is a large cytoskeletal protein that bridges the actin cytoskeleton to the extracellular matrix through the dystrophin-associated glycoprotein complex (DGC). Key DGC components include alpha- and beta-dystroglycan, sarcoglycans (alpha, beta, gamma, delta), sarcospan, syntrophins (alpha1, beta1, beta2), and dystrobrevins (alpha, beta). Dystrophin transcription is regulated by MyoD, MEF2C, YY1, and PAX3, while it scaffolds signaling molecules such as neuronal nitric oxide synthase (nNOS) via syntrophin interactions. This complex integrates mechanical signals with intracellular pathways, including MAPK/ERK, PI3K/Akt, and NF-??B, which control cell survival, proliferation, and migration. Disruption of dystrophin can lead to aberrant activation or suppression of these cascades, affecting cellular responses to extracellular cues.
In the p53-deficient, KRAS wild-type NCI-H1299 lung adenocarcinoma background, DMD knockout eliminates dystrophin protein, destabilizing the DGC and weakening cell-extracellular matrix adhesion. This loss is predicted to alter mechanotransductive signaling through MAPK/ERK and PI3K/Akt, thereby influencing migratory and invasive properties that are hallmarks of the host line??s metastatic origin. The model provides a platform to dissect dystrophin??s potential tumor-suppressive functions and its interplay with oncogenic drivers in lung cancer progression.
Representative applications include Western blotting and immunofluorescence for assessing DGC integrity, Boyden chamber migration/invasion assays, cell-matrix adhesion assays, phospho-protein arrays for pathway analysis, and transcriptomic profiling via RNA-seq or RT-qPCR. Additional uses encompass cell proliferation assays, drug sensitivity screening, and CRISPR validation experiments. This polyclonal knockout model is valuable for studying dystrophin biology in non-muscle cancers and for translational research in muscular dystrophy. For further information, contact Ascent Research.
